# Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus

> **NCT06731218** · PHASE1 · RECRUITING · sponsor: **Hangzhou Reprogenix Bioscience, Inc** · enrollment: 10 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** RGB-5088

## Key facts

- **NCT ID:** NCT06731218
- **Lead sponsor:** Hangzhou Reprogenix Bioscience, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06731218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06731218, "Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06731218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*